Core Laboratories (CLB) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
18 May, 2026Executive summary
Annual meeting scheduled for May 12, 2026, at Hotel Zaza, Houston, Texas, for shareholders of record as of March 18, 2026.
Proxy materials, including the notice, proxy statement, and annual report, are available online and by request.
Shareholders can vote in person, by internet, or by mail, with instructions provided for each method.
Voting matters and shareholder proposals
Proposal to re-elect two Class I Directors, Harvey Klingensmith and Curtis Anastasio, to serve until the 2029 annual meeting.
Proposal to ratify KPMG LLP as independent registered public accountants for the year ending December 31, 2026.
Advisory vote to approve executive compensation philosophy, policies, and procedures as described in the Compensation Discussion and Analysis.
Board recommends voting FOR all proposals presented.
Board of directors and corporate governance
Board recommends re-election of two current directors for a new term ending in 2029.
Latest events from Core Laboratories
- 2025 meeting covers director elections, auditor ratification, and performance-based executive pay.CLB
Proxy filing18 May 2026 - Votes will address director elections, auditor ratification, and executive compensation approval.CLB
Proxy filing18 May 2026 - Sequential revenue and margin growth, 21% net income rise, and share buybacks marked Q3 2025.CLB
Q3 202518 May 2026 - Proxy covers director elections, auditor ratification, and executive pay, with strong ESG focus.CLB
Proxy filing18 May 2026 - Q1 2026 revenue and margins fell on geopolitical and weather disruptions; modest Q2 rebound expected.CLB
Q1 202618 May 2026 - Q4 revenue up 7% year-over-year; Q1 2026 guidance: $124–$130M revenue, $0.11–$0.15 EPS.CLB
Q4 20255 Feb 2026 - Q2 2024 delivered higher margins, strong cash flow, and international growth despite U.S. softness.CLB
Q2 20243 Feb 2026 - Q3 2024 delivered 7% revenue growth, margin gains, and record-low leverage on strong international demand.CLB
Q3 202418 Jan 2026 - Full-year growth in revenue and EPS, strong cash flow, and improved leverage amid global risks.CLB
Q4 20249 Jan 2026